13F Holdings
中文EN

CUVL Clinuvel Pharmaceuticals Ltd Annual reports only

American Depositary Receipts · Nasdaq · SEC CIK 1290877 · Fiscal year ends 06/30

Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.2%
TTM net income YoY0.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin82.9%
Operating margin43.4%
Net margin36.0%
FCF margin18.4%
EBITDA margin44.0%

Returns

ROE13.4%
ROA12.2%
ROIC (approx.)12.6%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets7.5%
Debt / equity0.00x
Current ratio14.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio5.4%
Payout ratio7.2%
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30
Income statement
Revenue$64.32M$61.12M$57.91M
Cost of revenue$10.98M$11.51M$10.74M
Gross profit$53.34M$49.61M$47.17M
R&D expense$12.23M$13.22M$9.99M
SG&A expense$7.38M$6.68M$6.81M
Operating income$27.92M$26.52M$28.53M
Pretax income$32.72M$33.09M$33.22M
Income tax$9.54M$9.97M$9.87M
Net income$23.18M$23.12M$23.35M
EBITDA$28.31M$27.03M$29.02M
EPS (basic)0.460.460.47
EPS (diluted)0.460.460.46
Weighted avg. shares (diluted)50.75M50.38M51.03M
Banking
Deposits$160.10M$127.46M—
Balance sheet
Cash & equivalents$13.91M$18.06M—
Short-term investments$160.10M$127.46M—
Receivables$16.19M$17.75M$17.51M
Inventory$4.76M$5.73M—
Current assets$196.53M$170.70M—
PP&E, net$5.05M$4.51M—
Intangibles$127,892$120,331—
Total assets$203.98M$176.74M—
Current liabilities$13.35M$17.63M—
Total liabilities$15.36M$20.00M—
Shareholders' equity$188.62M$156.74M$135.03M
Shares outstanding50.43M50.12M—
Cash flow statement
Operating cash flow$12.91M$27.30M$23.75M
Capital expenditure$1.06M$190,593$3.65M
Free cash flow$11.85M$27.10M$20.10M
Investing cash flow-$25.64M-$30.62M-$19.25M
Financing cash flow-$1.67M-$1.87M-$2.09M
Depreciation & amortization$390,345$508,875$493,710
Stock-based compensation$1.59M$1.30M$4.07M
Dividends paid$1.67M$1.69M$1.59M
Share buybacks—$173,965$497,659

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.